It was reported that an erbe system, argon plasma coagulator (apc)/electrosurgical unit [esu/generator, model vio 3, part number (p/n) 10160-000, serial number (s/n) (b)(6)] system with a waterjet model erbejet 2, p/n 10150-000, s/n (b)(6)] was involved in a patient incident after a treatment as part of the endoscopic gastric mucosal ablation (gma) as a primary obesity therapy early feasibility [comet ef] - step ii study.The equipment was used with an erbe hybrid apc probe (p/n 20150-015, lot number wo378668), erbe nessy return electrode (p/n 20193-074, lot number 220711-2401), and erbe waterjet pump cartridge (p/n 20150-300, lot number wo379463).The equipment settings were per the study protocol.Per provided documentation, the accessories used in the procedure (treatment) on (b)(6) 2023 were discarded.The following information was provided as part of the documentation for the study.Briefly describe the event: on (b)(6) 2023, patient (b)(6) presented to ed at 19:30.Patient reported three episodes of hematemesis, luq pressure, and nausea beginning at 19:00 on (b)(6) 2023.Ed reported patient as tachycardic but normotensive.Patient underwent endoscopic evaluation to second part of duodenum, performed by pi at 22:20.Findings included a large clot in the fundus, no active gastric bleeding, and large, clean-based ulceration in the greater curve of the stomach.Detail of action / treatment taken: chest x-ray: unremarkable.Ekg: sinus tachycardia, normotensive.Egd: clot was removed in piecemeal fashion with a snare.A suspected visible vessel was discovered at the very proximal, superior aspect of the ablation in a cratered area.2ml epinephrine, 2 hemostatic clips, and 3ml purastat were applied to the suspected vessel.Patient was admitted overnight for observation and prescribed carafate, 1g, qid.Treatment or medication administered: medication: epinephrine, dose (unit, route of administration): 2ml, submuc., date of first administration: (b)(6) 2023, date of last administration: (b)(6) 2023.Medication: purastat, dose (unit, route of administration): 3ml, submuc., date of first administration: (b)(6) 2023, date of last administration: (b)(6) 2023.Medication: carafate, dose (unit, route of administration): 1g, qid, oral, date of first administration: (b)(6) 2023, date of last administration: ongoing when reported on (b)(6) 2023 medication: pantoprazole, dose (unit, route of administration): 40mg, iv, date of first administration: (b)(6) 2023, date of last administration: (b)(6) 2023.
|